01

AbbVie Reports Positive Phase 2 APEX Part B Results for Zumilokibart

AbbVie presented positive Phase 2 APEX Part B results for the IL-13 inhibitor zumilokibart in moderate to severe atopic dermatitis as a late breaker at EADV 2026.